



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

6 May 2026
EMA/HMPC/10132/2024
Committee on Herbal Medicinal Products (HMPC)

Assessment report on *Fragaria vesca* L.; *Fragaria moschata* Weston; *Fragaria viridis* Weston; *Fragaria x ananassa* (Weston) Duchesne ex Rozier, folium

Final - Revision 1

Based on Article 16d (1), Article 16f and Article 16h of Directive 2001/83/EC (traditional use)

Herbal substance(s) (binomial scientific name of the plant, including plant part)	<i>Fragaria vesca</i> L.; <i>Fragaria moschata</i> Weston; <i>Fragaria viridis</i> Weston; <i>Fragaria x ananassa</i> (Weston) Duchesne ex Rozier, folium
Herbal preparation(s)	Comminuted herbal substance
Pharmaceutical forms	Comminuted herbal substance as herbal tea for oral use
Rapporteur(s)	E, Widy-Tyszkiewicz (first version)
	W. Dymowski (revision 1)
Assessor(s)	W. Dymowski (first version)
Peer-reviewer(s)	O. Palomino (first version, revision 1)



Table of contents

Table of contents	2
1. Introduction.....	4
1.1. Description of the herbal substance(s), herbal preparation(s) or combinations thereof .	4
1.2. Search and assessment methodology.....	6
1.3. Main changes introduced in the 1 st revision	7
2. Data on medicinal use.....	7
2.1. Information about products on the market.....	7
2.1.1. Information about products on the market in the EU/EEA Member States	7
2.1.2. Information on products on the market outside the EU/EEA.....	8
2.2. Information on documented medicinal use and historical data from literature.....	8
2.3. Overall conclusions on medicinal use.....	10
3. Non-Clinical Data	11
3.1 Overview of available pharmacological data regarding the herbal substance(s), herbal preparation(s) and relevant constituents thereof.....	11
3.1.1. Primary pharmacodynamics	11
3.1.2. Secondary Pharmacodynamics	12
3.1.3. Pharmacodynamic interactions	15
3.1.4. Conclusions	15
3.2. Overview of available pharmacokinetic data regarding the herbal substance(s), herbal preparation(s) and relevant constituents thereof.....	15
3.3. Overview of available toxicological data regarding the herbal substance(s)/herbal preparation(s) and constituents thereof	15
3.3.1. Single dose toxicity.....	15
3.3.2. Repeated dose toxicity	16
3.3.3. Genotoxicity	16
3.3.4. Carcinogenicity	16
3.3.5. Reproductive and developmental toxicity	16
3.3.6. Local tolerance.....	16
3.3.7. Other special studies.....	16
3.3.8. Conclusions	17
3.4. Overall conclusions on non-clinical data.....	17
4. Clinical Data.....	17
4.1. Clinical pharmacology	17
4.1.1. Overview of pharmacodynamic data regarding the herbal substance(s)/preparation(s) including data on relevant constituents.....	17
4.2. Clinical Efficacy.....	17
4.2.1. Dose response studies.....	17
4.2.2. Clinical studies (case studies and clinical trials).....	17
4.3. Clinical studies in special populations (e.g. elderly and children)	18
4.4. Overall conclusions on clinical pharmacology and efficacy	18
5. Clinical Safety/Pharmacovigilance.....	18
5.1. Overview of toxicological/safety data from market overview	18
5.2. Patient exposure	18

5.3. Adverse events, serious adverse events and deaths	18
5.4. Laboratory findings	18
5.5. Safety in special populations and situations	19
5.5.1. Use in children and adolescents	19
5.5.2. Contraindications.....	19
5.5.3. Special Warnings and precautions for use	19
5.5.4. Drug interactions and other forms of interaction	19
5.5.5. Fertility, pregnancy and lactation	19
5.5.6. Overdose	19
5.5.7. Effects on ability to drive or operate machinery or impairment of mental ability.....	20
5.5.8. Safety in other special situations	20
5.6. Overall conclusions on clinical safety	20
6. Overall conclusions	20
Annex	22

1. Introduction

1.1. Description of the herbal substance(s), herbal preparation(s) or combinations thereof

- Herbal substance(s)

Fragariae folium is defined in the Austrian Pharmacopoeia (Österreichisches Arzneibuch 2013) as "The collected, dried leaves of *Fragaria vesca* L., *Fragaria moschata* Weston, *Fragaria viridis* Weston, *Fragaria x ananassa* (Weston) Duchesne ex Rozier or a mixture of these species". Content: at least 3.0 percent of tannins, expressed as pyrogallol (C₆H₆O₃; Mr 126.1) and based on the dried drug.

Common wild strawberry (*Fragaria vesca* L., Rosaceae) is a perennial plant growing in meadows, woods (Mabberley 2002), native across Northern Europe to the Ural Mountains and in North America. *Fragaria vesca* L., diploid (2x), have been cultivated since the Middle Ages in European gardens. Various strawberry cultivars originate from a random hybridisation of two wild American octoploid (8x) species *Fragaria chiloensis* L. and *Fragaria virginiana* (Gündüz 2016). The leaves are collected also from cultivated octoploid strawberry *Fragaria ananassa* (8x) (Sargent *et al.* 2009) and two wild species growing in European forests *F. moschata* L. (hexaploid) and *F. viridis* Duchesne (diploid). Chromosome number is used to differentiate *Fragaria* species by use of genetic barcoding (Lundberg *et al.* 2009; Rousseau-Gueutin *et al.* 2009). Comparative taxonomic morphological and anatomical studies of collected leaves of several *Fragaria* species in various parts of Austria were conducted by Scheller (2013).

In the European traditional medicine, wild strawberry leaves, collected during the flowering period, or cultivars which are mostly harvested in the wild by rural populations in Albania, Bulgaria, Croatia, Kosovo, Serbia, North Macedonia and Ukraine are used (Medicinal Plants and Natural Ingredients, 2015).

Constituents of *Fragariae folium* relevant for this assessment report

Free and condensed tannins. Lamaison 1990, Scholz monograph in Hagers 5th edition (1993), Blaschek (HagerRom 2006), estimated 5-10% tannins. Oktyabrsky *et al.* (2009) reported *Fragariae folium* total tannin content of 8.2 mg/g (dry weight) in *Fragaria vesca* leaves ethanol extract. In a strawberry leaf decoction (15g in 150ml, 1.44 g of dry content), as minor peaks of phenolics (beside of soluble sugars) Mudnic *et al.* (2009) identified: epicatechin gallate, astringin, (+)-catechin and (-)-epicatechin. In the infusion (4 g in 200 ml) the main catechins were: (+)-catechin, sanguin H10 isomer and procyanidin dimer, epicatechin hexoside and B type epicatechin trimer (Ivanov 2015, 2018).

Phenolic acids. Phenolic acids were referred to be present in the leaves of *Fragaria vesca*, *Fragaria viridis*, *F. moschata* as 3.4% of phenolic acids (Blaschek *et al.* 2006). Najda and Dyduch (2009a) found 1.8% of phenolic acids in *Fragaria vesca* dry leaf weight and 1.3% in its cultivar 'Regina'. Dyduch and Najda (2009) found in dry *Fragaria vesca* cultivars 1.0-1.13% of phenolic acids in leaf blades and 0.13-0.20% in petioles. Ellagic acid was contained in 0.20-0.23%, gallic acid in 0.11-0.16% (Fecka, 2009). Methanolic extract of *Fragaria vesca* leaves contained gallic acid monohydrate, vanillic acid, caffeic acid and p-coumaric acid (Yildirim and Turker 2014). 2-pyrone-4,6-dicarboxylic acid was found in *Fragaria vesca* in 0.21% and in *Fragaria ananassa* 0.24%, Wilkes and Glasl (2001). Akšić *et al.* (2019b) found in acidified extract of strawberry leaf (methanol-water 7:3, v/v with 0.1% HCl) also small quantities of 5-O-caffeoylquinic acid.

Other constituents of strawberry leaf

Soluble sugars are dominating constituents of strawberry leaves hot water and alcohol extracts. (Dias *et al.* 2015a) in hot water extract of the fresh freeze-dried leaves and stems estimated sum of soluble sugars 31.7%; sucrose 8.5%, glucose 7.4%, fructose 6.4%, xylose 5.8%, trehalose 3.6%. Akšić *et al.* 2019a found average content of 10.4 – 19.5% sugars in leaves of common cultivars.

The main characteristic group of strawberry leaf are oligomeric procyanidins derived from catechin, which were found in alcohol extracts by Stafford and Lester (1980). In methanol water extracts (1:1, w/v) of dry *Fragaria vesca* leaf were determined mainly 0.89-1.11% of agrimoniin and 0.40-0.68% of pedunculagin and 0.21-0.25% of catechin (Fecka, 2009). Yildirim and Turker (2014) found: pyrocatechol, (–) epigallocatechin, (+) catechin, procyanidin B1, B2, C1, (–) epicatechin, agrimoniin, pedunculagin, and other oligomeric (laevigatin isomers and sanguin H-10 isomer, castalagin/vescalagin isomer, sanguin H-2 isomer, casuarictin/potentillin isomer, sanguin H-6/agrimoniin, lambertianin A isomer (Liberal *et al.* 2015) and monomeric ellagitannins (casuarictin, agrimonic acid A/B, isostrictinin/sanguin H-4) with the total content of 5.2-8.9% ellagitannins in a hydro-methanolic crude extract (Moilanen *et al.* 2015). Maximum content of 12.4% procyanidins (B1, B2 and B5) from *Fragaria vesca* leaves was found in 56% acetone-water extract (Ivanov 2015). Last years, Karlińska *et al.* (2021) studied content of ellagitannins in the extract (70/29.9/0.1 (v/v/v) acetone/water/formic acid) of fresh leaves of six strawberry cultivars in four stages: leaf development (S1), flowering (S2), fruit development (S3) and fruit and achene maturation (S4) with maximum content 5.9-15.2% of ellagitannins in leaf development stage. In the acetone-water extract of post-harvest leaf of *Fragaria x ananassa* cv. Senga sengana (Fecka *et al.*, 2022) found 3- and 5-O-galloylquinic acid, pedunculagin and agrimoniin.

Flavonoid glycosides. Najda and Dyduch (2009a), Dyduch and Najda (2009) reported that leaves from cultivated species (*Fragaria vesca* "Regina") contained more flavonoids (4%) as compared to the herb collected from natural habitats (3%). In the methanolic extract Yildirim and Turker (2014) shown the presence of luteolin-7-O-D-glucoside, rutin hydrate, myricetin, kaempferol-3-d-glucopyranoside, daidzein, quercetin, genistein and apigenin. The extracts from leaves with 50 acidified water and 80% ethanol contained mainly quercetin-3-O-rutinoside and its -3-O-glucuronide (Oszmiański *et al.* 2011). Wild strawberry leaves contained 2.16mg/g (0.22%) quercetin and 0.34mg/g [0.34%] kaempferol (Haghi and Hatami, 2010). The flavonoid content in the leaves *Fragaria vesca* was observed to decrease when growing in higher altitudinal zones of western Carpathian Mountains (Malinikova *et al.* 2013).

Terpenes. The air-dried leaves contained small amounts of essential oil, depending on the cultivar, from 0.46% (cv 'Baron von Solemacher') to 0.62% (cv 'Rugia') with dominated myrthenol, nonal, linalool and dibutyl phthalide (Najda and Dyduch 2009b). Hampel *et al.* (2006) found in GC-MS of *Fragaria vesca* leaves (R)-linalool with a high enantiomeric purity (>90%). Gleńsk *et al.* (2021) isolated from strawberry leaves triterpenoid constituents with main glycoside nigaichigoside F1.

Constituents of Fragariae folium infusions and decoctions

Mudnic *et al.* (2009) in a strawberry leaf decoction (15 g in 150 ml, 1.44 g of dry content after evaporation) identified as minor peaks in phenolics: epicatechin gallate, astringin, (+)-catechin, (–)-epicatechin and smaller amounts of quercetin-4'-glucoside and procyanidin B1 (HPLC-RP-DAD, 330 nm, RP18 column). Liberal *et al.* (2014) analysed phenolic profile of the strawberry leaf infusion (4g in 150 ml, w/v) by HPLC-PDA-ESI/MSn method with mass analyses in negative ion mode. The infusion shows presence of kaempferol glucuronyl-rhamnoside and quercetin glucuronide, quercetin glucuronyl-rhamnoside, methyl elagic acid rhamnoside, sanguine H-6/agrimoniin, epiafzelechin-epicatechin, quercetin hexosyl-glucuronide, unidentified elagic acid derivative and smaller quantities of casuarictin/potentillin, castalagin/vescalagin and epicatechin-epicatechin. According to Dias *et al.*

(2015a, 2015b), herbal teas prepared from *Fragaria vesca* leaves and stems (2 g in 200 mL), contain soluble sugars (primarily glucose and fructose), organic acids (citric and malic) and manganese. The flavonoid compounds in these infusions were dominated by quercetin O-glucuronide and rutoside, methyl quercetin and quercetin deoxyhexose glucuronides, kaempferol deoxyhexose glucuronide, and quercetin hexose glucuronide. As catechin related compounds in the infusions were identified: (+)-catechin, sanguin H10 isomer and procyanidin dimer, epicatechin hexoside and B type epicatechin trimer. Ivanov (2015, 2018) determined in *Fragariae folium* infusions and decoctions (4 g/200 ml) total phenolics contents of 107 and 129 GAE/g and tannin contents (spectrophotometric method) between 46 and 53 mg/g. Furthermore, procyanidin contents determined as leucocyanidin equivalent ranged from 116 and 134 mg LE/g.

- Herbal preparations described in pharmacopoeias and national codexes

There are no preparations of strawberry leaf in the European Pharmacopoeia and national codexes.

The only used in the EU countries is herbal tea, infusion (see above).

- Combinations of herbal substance(s) and/or herbal preparation(s) including a description of vitamin(s) and/or mineral(s) as ingredients of traditional combination herbal medicinal products assessed, where applicable.

Not applicable.

1.2. Search and assessment methodology

Scientific databases

☒ Scientific/Medical/Toxicological databases

Search terms: *Fragaria*; *Fragaria vesca*, *Fragaria moschata*, *Fragaria viridis*, *Fragaria x ananassa* strawberry leaves. Databases: PubMed, Embase, Medline, Scopus, Toxnet. The search was performed between June 2015 and May 2017 and between June and December 2023. Libraries: Library of Warsaw Medical University, Department of Pharmacognosy and Pharmacology, Faculty of Pharmacy of the University Complutense of Madrid, Spain

☒ Pharmacovigilance databases

☒ data from EudraVigilance

☒ from other sources (e.g. data from VigiBase)

☒ Other. National database. Poland

Books

☒ New editions of old manuals were searched for

Regulatory practice

☒ Old market overview in AR (i.e. check products fulfilling 30/15 years of TU or 10 years of WEU on the market).

☒ Market overview (including pharmacovigilance actions taken in member states)

☒ PSUSA. Not applicable, no medicinal products are available

☒ Feedback from experiences with the monograph during MRP/DCP procedures. Not applicable, no medicinal products are available

☒ Ph. Eur. Monograph. No monograph is available in the European Pharmacopoeia

☒ Other: There is a monograph for strawberry leaf in Austrian Pharmacopoeia (Österreichisches Arzneibuch 2013)

Consistency (e.g. scientific decisions taken by HMPC)

☒ Public statements or other decisions taken by HMPC

☒ Consistency with other monographs within the therapeutic area

☐ Other

1.3. Main changes introduced in the 1st revision

1. Chapter 1.1 on herbal substance is shortened and part on herbal preparations (herbal tea, infusion) is updated.
2. Chapter 2.2 is updated
3. Chapter 3.1.1 on primary pharmacodynamics is restructured in line with the new template.
4. Chapter 3.1.2 on secondary pharmacodynamics is shortened in line with a new template and updated.
5. Chapter 4.2.2 'on clinical studies is updated and the corresponding safety sections are aligned with related monographs with the same therapeutic indication.

2. Data on medicinal use

2.1. Information about products on the market

2.1.1. Information about products on the market in the EU/EEA Member States

Information on medicinal products marketed in the EU/EEA

There are no registered or authorised medicinal products in the EU/EEA Member States according to information provided by the national competent authorities upon inquiry in preparation of this Assessment Report.

The overview is not exhaustive. It is provided for information only and reflects the situation at the time when it was established.

Overview of data obtained from non-marketed medicinal products

No data available.

Information on relevant combination medicinal products marketed in the EU/EEA

No data available.

Information on other products marketed in the EU/EEA (where relevant)

Strawberry leaves are included as part of several multi-component preparations marketed as food supplements in the EU, intended 'to improve metabolism' or for improving taste of traditional tinctures (in Poland).

2.1.2. Information on products on the market outside the EU/EEA

Wild strawberry leaves are widely used especially in Serbia, as herbal tea (infusion), to treat diarrhoea (Šavikin *et al.* 2013); to treat cough (Zlatković *et al.* 2014a); as antidiarrheal, anthelmintic, diuretic, blood purifier, for relieve pain from kidney stone and in liver and bladder area; as antigout (Jarić *et al.* 2007); laxative or in diarrhoea and haemorrhoids (Zlatković and Bogoslavljević 2014a,b). The tea from young leaves is used as antitussive, to ‘heal’ asthma, catarrh and cough; a tea from ‘herbal parts’ is used as nerve relaxant (Popović *et al.* 2014).

2.2. Information on documented medicinal use and historical data from literature

In the old European tradition wild strawberry leaf was used as an astringent for diarrhoeas (especially *summer diarrhoea*), jaundice, abdominal congestion, as an intestinal tonic, and as a mild diuretic (Kosch 1939). *Summer diarrhoea* was named paediatric diarrhoeas occurring in Europe, America and Southern Africa during the summer in infants and children (Ebbs 1957, Robins-Browne *et al.* 1980) although since the 1950s this disease in Europe and America becomes less frequent (Anderson *et al.* 2020, Mallier *et al.* 2023). For diarrhoea in children and adolescents a decoction made of 1-2 tablespoons in a glass of water or the infusion of 4.0 g in 150 ml of water cup, used as a single dose, were referred (Ożarowski 1978, Blaschek HagerRom 2006).

As a mild diuretic was reported the use of hot infusion made of one tablespoon of herbal substance in one cup of water, taken twice daily (Kosch 1939) or the infusion of one tablespoon in one glass of water, taken in a quantity of ¼ of glass twice daily.

Beside of the use of wild strawberry leaves as infusion or decoction in the treatment of diarrhoea, especially for children, it has been mentioned the use for the inflammation of oral mucosa and throat (as gargles) and in urinary-tract diseases (Dragendorff 1898, Schneider 1974, van Wyk and Wink 2004, Wren 1975) and in rheumatism and gout. Blaschek *et al.* (HagerRom 2006) referred mainly internal use of folk medicines prepared as follows: Boil a handful of young leaves in 500 ml of water for diarrhoea. The decoction of 375 g of fresh green leaves in 1.15 l boiled water until the volume reduces to 550 ml and condensed preparation was dosed with a teaspoon every 3-4 hours. 20 g of fresh leaves in 500 ml of boiled water until its volume reduces to half of the initial volume and it is used one teaspoon before and one after a sleep. Although in the folk medicine mainly fresh leaves were used to prepare a decoction for gargles and the treatment of oral mucosa inflammation, in this assessment are included only data on dried strawberry leaf, as defined in Chapter 1.1.

Also in South European folk medicine of Bulgaria, Italy, Spain and Portugal the *Fragaria vesca*, *Fragaria viridis* and *Fragaria moschata* leaves, leaves were used as a herbal teas as diuretic and in gout (Akerreta *et al.* 2007, Nedelcheva *et al.* 2010, Leporatti and Ivancheva 2003, Camejo-Rodrigues *et al.* 2003, Neves *et al.* 2009); as astringent in diarrhoea and stomatic diseases; throat and mouth diseases as anti-inflammatory and topically on the skin in wound treatment (Tuttolomondo *et al.*, 2014, Nedelcheva *et al.* 2010, Leporatti and Ivancheva 2003, Akerreta *et al.* 2007).

Table 1 shows a summary of the traditional uses of strawberry leaves.

Table 1: Overview of historical data

Herbal preparations	Documented use/Traditional use	Posology and method of administration	Reference and date of reference
Fragariae folium	As an astringent for diarrhoea (<i>summer</i>	Oral hot infusion. 1 tablespoon in 1 cup, 2 cups	Kosch 1939

	<i>diarrhoea</i>), jaundice, abdominal congestion, as an intestinal tonic, and as a mild "opening" diuretic.	daily	
Fragariae folium	Oral use as diuretic	Oral use. 1 tablespoon ¹ (5 g on average) of the leaves in a glass of water as decoction. Drink ¼ of glass ² of the prepared decoction 2 times daily	Bobowska <i>et al.</i> 1977
Fragariae folium	Oral use as weak diuretic in gout and urinary tract calculitis. For children in mild diarrhoeas as astringent. Used especially in herbal tea combinations.	Decoction. 1-2 tablespoons (5-10 g on average) for 1.5-2 glasses of water. Drink a half of glass ml 2-3 times daily; in children 1/4 -1/3 of a glass.	Ożarowski 1976, Ożarowski <i>et al.</i> 1978
<i>Fragaria vesca</i> L., leaf	In mild diarrhoeas in children. Also declared to possess diuretic and antispasmodic properties.	Infusion for oral use. Strength: 1-2 tablespoons pour with 1.5-2 glasses of boiling water for 15 min. The prepared infusion is kept in a thermos and given to children in dose of half of glass.	Olechnowicz-Stępień, Lamer-Zarawska 1986
<i>Fragaria vesca</i> L., leaf	Astringent. Folk use for mild diarrhoea in children	Infusion with 4 g of drug per 150 ml as a single dose for children's diarrhoea	Hänsel <i>et al.</i> (red.) Hagers Handbuch Vol. V, 1993
<i>Fragaria vesca</i> L., dried leaf	Folk use for mild diarrhoea especially in children	Oral use: Infusion of 4 g of drug in 150 ml as a single dose for children's diarrhoea.	Blaschek <i>et al.</i> HagerROM 2006
<i>Fragaria vesca</i> L. as herbal tea	1. Topical use in mouth and throat infection. 2. Internal oral use as diuretic and in diarrhoea	Decoction: 5 g of the leaves in 100 ml of water. Gargle the mouth and throat several times a day. Infusion: 4 g in 100 ml of water. Drink 3-4 times a day a small cup	Wurzer 1994

¹ Average spoons used in Poland over the last 30 years have contained 4.4±0.5g - 5.5±0.6g of *Fragariae folium* dried herbal substance, (Dymowski & Jackiewicz, 2020)

² Average glass used in Poland over the last 30 years have contained about 200 ml

2.3. Overall conclusions on medicinal use

The evidence on the period of medicinal use for *Fragaria* leaves is limited to those references including all the species, with a traditional indication and posology (Table 2).

In the monograph, the posology of *Fragaria vesca* leaves as a diuretic in patients with mild urinary symptoms was calculated based on the publications of Ożarowski *et al.* 1978 and Bobowska *et al.* 1977.

Table 2. Overview of evidence on period of medicinal use.

Herbal substance/ preparation	Indication	Posology and method of administration	Period of medicinal use
Fragariae folium. Herbal tea, infusion	As astringent in mild diarrhoea in children, and as mild diuretic	Oral use. Hot infusion made of 1 tablespoon in 1 cup, 2 times daily	Kosch 1939
Fragariae folium. Herbal tea, decoction	Oral use as diuretic	Oral use. 1 tablespoon (5 g on average) of the leaves as a decoction for 200 ml of water. Posology: Drink 50 ml 2 times daily	Bobowska <i>et al.</i> 1977
Fragariae folium. Herbal tea, decoction	Oral use as weak diuretic (gout, urinary ways calculitis) and astringent mainly for diarrhoeas in children	Oral use. 1-2 tablespoons (5-10 g on average) for 1.5-2 glasses of water (300-400 ml) as decoction. Posology: Drink ½ of glass (100 ml) 2-3 times daily; for children: 1/4 -1/3 of a glass (50-60 ml)	Ożarowski 1976, Ożarowski <i>et al.</i> 1978
<i>Fragaria vesca</i> L., leaf	Astringent. Folk use for mild diarrhoea in children	Infusion with 4 g of drug per 150 ml as a single dose for children's diarrhoea	Hänsel <i>et al.</i> (red.) Hagers Handbuch Vol. V, 1993

Historical data in the EU support the evidence of traditional use of comminuted *Fragaria* leaves:

In adults and elderly in Indication 1) Traditional herbal medicinal product used for the relief of symptoms associated with minor urinary tract complaints in addition to the general recommendation of a sufficient fluid intake to increase the amount of urine.

In children and adolescents in Indication 2) Traditional herbal medicinal product for symptomatic treatment of mild diarrhoea.

The historical and bibliographic data are consistent in the use as mild astringent in diarrhoeas in children, although the traditional data are not adjusted to the contemporary paediatric age groups. However, the use of the infusions/decoctions is less documented in adults but by some of experts is estimated as plausible.

3. Non-Clinical Data

3.1 Overview of available pharmacological data regarding the herbal substance(s), herbal preparation(s) and relevant constituents thereof

3.1.1. Primary pharmacodynamics

3.1.1.1 Diuretic effect

Although wild strawberry leaves are traditionally used to promote urine flow, the studies conducted to evaluate the diuretic activity are scarce and results are not conclusive. In rats, the decoction of the leaves (10 g in 100 ml) in doses corresponding to 1 g drug/kg b.w. did not have any significant influence on diuresis following oral administration while positive control of probenecid 25 mg/kg b.w. and other substances used traditionally, like barley grain, coriander and parsley fruits gave important increase of urine excretion (Caceres *et al.* 1987). The extract made from 0.5 g dried leaves with 20 ml ethanol 50% at a concentration of 100 µl/2.5 ml medium inhibited the proteolytic activity of the enzyme elastase by 85%. However, no data on the effect of a positive control are available (Blaschek *et al.* 2006).

3.1.1.2 Astringent/antidiarrheal effect

Fragaria leaves due to their tannin content may have plausible astringent effects (Hänsel *et al.* 1993, HagerROM 2006) and have been used for mild diarrhoeas, especially in children (Kosch 1939, Olechnowicz-Stępień & Lamer-Zarawska 1986, Ożarowski *et al.* 1978) although there are no available experimental studies on animals to support this indication.

Table 3. Overview of the main non-clinical data.

Herbal preparation tested	Concentration/ Dosage	Experimental model	Reference	Main outcome(s) according to the authors
Data on diuretic effect of herbal tea, decoction				
Strawberry leaf decoction of 10g in 100ml	Dose of the decoction corresponded to 1g/kg b.w.	In vivo test. 6 inbred albino rats, weight 220-289g, of the same sex and age, kept controlled animal colony conditions. The decoction was administered at by the catheter. Urine was collected at 2, 4 and 6h. The urinary growth output was expressed percent of the control output. Positive control hydrochlorothiazid e 25mg/kg b.w.	Caceres <i>et al.</i> 1987	The urinary output was below 90% of growth what authors classified as weak or no effect (medium effects 90%-180%). Hydrochlorothiazide control gave 286% of growth
Data on of other preparations (ethanol extract, tincture)				
Strawberry leaf fluid extract	The dried fluid extract was	In vivo. Diuretic effect was	Vicas <i>et al.</i> , 2015	In two rats with an oral dose of 15 mg/100 g of

Herbal preparation tested	Concentration/ Dosage	Experimental model	Reference	Main outcome(s) according to the authors
(DER 1:2) extraction solvent ethanol 70% (v/v) with added 10% of propylene glycol; dried and dissolved in water. Tincture (1:2) with 90% (v/v) ethanol	administered to two rats in a dose of 15 mg/100g and to two rats in a dose 150mg/100g, orally in water solution; one administered with furosemide injection 20mg/100g as a positive control and one with water as a negative control	observed on group of 7 Wistar rats (average 200g) administered by oral gavage with a dose 15 mg/100g of the dried extract (what correspond 10 g in 70kg human) or the dose 10x higher 150 mg/100g, in compared to furosemide injection 20 mg/100g as a positive control and one with water as a negative control and water.		extract urine output over 10 h was observed 3.5 and 7 ml; in two rats with 150 mg/100 g 5 and 4 ml; in the injected with furosemide 4 ml. The analysis of sodium and potassium in the urine indicated stimulation of sodium elimination.

3.1.2. Secondary Pharmacodynamics

3.1.2.1. Anti-inflammatory activity - *in vitro*

Havlik *et al.* (2010) searched for the xanthine oxidase inhibitory properties *in vitro* among 27 extracts of plants, which were traditionally used in Central-Eastern Europe for gout, arthritis or rheumatism treatment. Three extracts of 5 g powdered *Fragaria vesca* leaves were prepared with 20% aqueous ethanolic, 80% aqueous ethanolic and methylene chloride–methanolic extracts (50/50 CH₂Cl₂/ MeOH) tested at the starting concentration 200 µg/ml did not show any evident effects.

Liberal *et al.* (2014) studied the anti-inflammatory activity of extracts from *Fragaria vesca* leaves extract with dichloromethane (1:10, w/v-2 times) and 50% aqueous ethanol (3 times) (1:10, w/v) at room temperature, filtrated and lyophilized (yield 30%). The extract (dissolved in phosphate buffered saline, PBS) was tested at non-toxic concentrations of 80 µg/ml and 160 µg/ml for NO production in the cultured mouse leukemic monocyte macrophage cell line Raw 264.7. Control cells produced very low NO levels (0.35±0.23 µM), the cells treated with LPS (for 24 hours) increase of NO content (28.64±2.10 µM); the cells pretreated with the tested plant extract (160 µg/ml and 80 µg/ml), gave significant decreases (40% and 31% respectively) of nitrite production. The extract tested at 160 µg/ml in experiment, where S-nitroso-N-acetyl penicillamine (SNAP) was used as NO donor in the culture medium, promoted significant decrease (23% of inhibition) of nitrite content. The extract tested on iNOS and COX-2 protein expression (Western blot method), shown no difference LPS-induced COX-2 protein levels compared with LPS alone (1480±499% of control) and not influenced the activity of LPS on mRNA levels of iNOS and IL-1β in mouse macrophages. The authors indicated that inhibition of the nitrite production by the extract is probably.

Assessor's comments:

Pharmacological experiments on possible anti-inflammatory and antimicrobial activities are generally in line with a traditional use, however observed only in substances from less polar extracts than water infusion (dichloromethane and/or alcohol extracts).

3.1.2.2. Antithrombin and anticoagulant activity - *in vitro*

Goun *et al.* (2002) determined the antithrombin activity of dry wild strawberry leaf extract (200 g extracted with methylene chloride for 24 hours, methanol 24 hours in a Soxhlet apparatus and the solvents were removed in vacuum). In parallel, the cytotoxic activity of extracts was tested on mouse leukaemia cells (L1210). The idea of the test was that the lower the activity of thrombin, the lower the coagulability, and therefore, the lower the possibility of tumour cells to adhere to any tissue or to spread. Both *Fragaria*'s extracts showed no antithrombin activity. The cytotoxicity tested at only one concentration (10 µg per well) was given with 77 % for the methylene chloride extract and 11% for the methanol extract.

Pawlaczyk *et al.* (2009; 2013) in extracts of strawberry leaves with methanol and acetone obtained 5 glycoconjugates (Fv I–FvV) composed of carbohydrates and phenolic and protein constituents with sugar component 21.1–31.7%, phenolic component 0.8–3.5% and protein components 0.5–1.8%. The main carbohydrate was hexuronic acid (31–61% of the carbohydrates) with other monosaccharides (Rh, Fu, Ar, Xyl, Ma, Gl, Glc) comparable to polysaccharide anticoagulants like glycosaminoglycans, i.e. heparin. Fractions Fv I–V were tested *in vitro* for their anticoagulant activity on human plasma by activated partial thromboplastin time test (aPTT), prothrombin time test (PT), and thrombin time test (TT) in the concentration range from 4000 µg/ml to 7.81 µg/ml and showed that only two glycoconjugates, i.e. Fv III and Fv I have a significant activity, but lower than that of unfractionated heparin. The most active conjugates contained similar amounts of galacturonic acid, and the highest amounts of phenolics.

3.1.2.3. Vasoactive effects – *ex vivo*

Vasodilatory activity of wild strawberry leaves decoction (15 g in 150 ml) dried with a yield of 1.44g and redissolved to a final concentration of 6 g/100 ml.) was studied on aortic rat rings endothelium-model *ex vivo*, exposed to nitric oxide (NO) synthase inhibitor L-NAME or to the cyclooxygenase inhibitor indomethacin (Mudnic *et al.* 2009). Isolated rat aortic rings (endothelium denuded and intact) were exposed to the extract concentrations: 0.06, 0.6, 6 and 60 mg/100 ml. The model rings were pretested by contraction induced with a test dose of noradrenaline (10^{-7} mol/l) and with subsequent relaxation acetylcholine (10^{-6} mol/l, 70% of relaxation). The relaxation of the rat aortic rings was expressed as the percentage decrease of NA-induced vasoconstriction. The maximum relaxation induced by the strawberry extract was 72.2 ± 4.45 . Removal of the endothelium caused a loss of vasodilatory response to the strawberry extract. The strawberry extract at only at higher dose (60.0 mg/100 ml) antagonised the inhibitory activity of indomethacin. Malheiros *et al.* (2022), studied the possible vascular effects of the *Fragariae folium* extract (pre-extraction with dichloromethane, extraction with 50% aqueous ethanol (3 x, 1:10, w/v) and the infusion (4g in 150 mL), freeze-dried (yield 23%) on human artery rings *ex vivo*. Both extract and infusion lyophilisate elicited no effect on vascular tone in the experiment.

3.1.2.4. Cardiac effects - *ex vivo*

The wild strawberry leaf dry decoction (as described in 3.1.2.3) was tested in guinea pig isolated hearts (Mudnic *et al.* 2009) at concentrations of 0.06, 0.18, 0.6, and 1.8 mg/100 ml. Each concentration was perfused for 3.5 minutes with 15 minutes of washout periods. Heart contractility, electrophysiological activity, coronary flow and oxygen consumption were continuously monitored. The heart rate was not influenced by application in all doses. The initial control values for heart rate, AV conduction time and LVP were 224 ± 6 beats per minute, 63 ± 2 ms and 92 ± 2 mm Hg, respectively. The initial control value of coronary flow was 13.1 ± 0.5 ml per minute. The extract at concentrations of 0.06, 0.18, 0.6, and 1.8 mg/100 ml increased coronary flow by 3.6 ± 1.2 , 8.4 ± 1.6 , 32.7 ± 5.0 and

44.5±4.5% over the control value, respectively. Oxygen extraction in the guinea pig hearts was significantly reduced by the consecutive doses of the extract as follows: by 3±1, 11±2, 27±2 and 34±4% from the control value of 78±2%; as a result of direct vasodilation.

3.1.2.5. Antimicrobial activity - in vitro experiments

Borah *et al.* (2012) evaluated the antimicrobial activity of water solutions of dry ethanolic extracts (percolation with ethanol 90%) of four medicinal plants, including *Fragaria vesca* leaves. An aqueous solution was used to determine the diameter of the inhibition zones in the agar cultures discs of bacteria. Standard commercial discs of ciprofloxacin (5 µg/ml) were used as a reference standard and ethanol (90%) impregnated discs were used as negative controls. The plates were incubated (37°C for 24 h) to estimate the antibacterial activity against selected bacterial strains of *Staphylococcus aureus*, *Escherichia coli*, *Pseudomonas aeruginosa*. Marked antibacterial effect has been found for the *Fragaria* leaves ethanolic extract (0.5 mg and 1 mg samples) against *S. aureus* (16.5 and 13.7 mm) and *Escherichia coli* strains (14.8 and 17.3 mm); ciprofloxacin zones (21.5-22.0mm). The *P. aeruginosa* showed less growth inhibition to the *Fragaria* extract compared to the other bacterial strains.

Pereira *et al.* (2012) investigated strawberry leaf ethanol extract fractions (eluted with 50% aqueous methanol [Fa], 75% aqueous methanol [Fb], and 70% aqueous acetone [Fc]) on metallo-beta-lactamase, MBL *Pseudomonas aeruginosa* clinical strain isolates (VIM-2 producers). For the determination of MICs against MBL VIM-2 producers *Pseudomonas aeruginosa* standard microplate assays were used. The tested extracts gave MICs as follows: crude extract (MIC₅₀=10.35 mg/ml, MIC₉₀=20.7 mg/ml); fraction Fa (MIC₅₀ and MIC₉₀=25 mg/ml); fraction Fb (MIC₅₀=6.25 mg/ml, MIC₉₀=12.5 mg/ml); fraction Fc (MIC₅₀ and MIC₉₀=12.5 mg/ml). The most active antibacterial fraction was the Fb (MeOH 75%) fraction consisting essentially of tannins: proanthocyanidins and ellagitannins. Weak antimycobacterial activity of higher concentration of the methanol extract of *Fragaria vesca* leaves was detected studied by Mc Cutcheon *et al.* (1997) and cited after in Newton *et al.* (2000). It was found that methanol extract induced of small zone of clearing of *Mycobacterium tuberculosis* at 50 µg extract per disc. No activity of the extract against *Mycobacterium avium* at 50 µg extract per disc has been found.

3.1.2.6. Antidiabetic activity - in vivo

Czapska-Pietrzak *et al.* 2019 found the extract of *Fragariae folium* rich in gallic acid and claimed it to be potentially antidiabetic. Shikov AN *et al.* (2021) mentioned *Fragariae folium* among herbal substances most frequently used in antidiabetic products in Russia. Ibrahim DZ & Abd El-Maksoud (2015) tested strawberry leaf extract (DER 2:1, extr. solvent water) in doses: 50, 100, 200 mg/kg to diabetic (streptozotocin induced) rats. The extract at the tested doses significantly decreased levels of blood glucose, urea nitrogen, plasma creatinine, renal malondialdehyde, TNF-alpha and IL-6 in the diabetic rats. LD₅₀ was found to be over 800mg/kg. Takacs J *et al.* (2020) studied the inhibition of alpha-glucosidase effect of the lyophilized decoction (3g in 300ml) of the *Fragariae folium* administered to normal mice, obese mice, prediabetic and diabetic (STZ) and in model of starch-induced rise in blood glucose level. The wild strawberry leaf extract alleviated starch induced hyperglycaemia in prediabetic and diabetic mice. Zhang L *et al.* (2020) administered water strawberry extract (100g of powdered material in 100ml of water, dried, 55% of dry residue) to Sprague-Dawley rats with STZ induced diabetes, where blood glucose raise over 200mg/dL. The authors observed alleviation of cognitive impairment, decrease of malonyl dialdehyde, decreased tmRNA expression of IL-6 and TNF alpha after 4 months of treatment.

3.1.2.7. Antioxidant activity - in vitro

Fragaria vesca water extract

Katalinic *et al.* (2006) determined antioxidant capacity of *Fragaria vesca* infusions (3 g of leaves or herb, in 200 ml) using the Ferric Reducing/Antioxidant Power (FRAP) at values of 0.06 to 25 mM/l finding an overall linear correlation between total phenolic content and FRAP (841 mg catechin equivalent/l and 11022 FRAP ($\mu\text{M/l}$)). *Fragaria vesca* infusions were found as a rich source of antioxidants. (Buricova & Reblova, 2008; Buricova *et al.* 2011) tested the antioxidant activity and phenolic content of wild strawberry leaves infusion (1 g in 50 ml), assessing total phenolics assay (Folin-Ciocalteu method) 62.4 mg of gallic acid/g; FRAP 23.3 mM FeSO_4/l ; oxygen radical absorbance capacity (ORAC) μM Trolox/g and free radical scavenging ability by the use of a stable DPPH radical 110.1 mg of ascorbic acid in dry sample. The radical scavenging capacities (TPC, DPPH, ORAC, FRAP) of the wild strawberry leaves infusions were determined to be in the range of about 50% of the antioxidant capacity of green tea water extract. (+)-Catechin, and ellagic acid significantly participated in the antioxidant activity of the infusion. Raudonis *et al.* (2012) estimated antioxidant activity with the range of total TEAC values 191.23–609.36 mol/g and 178.63–642.20 mol/g of ABTS and FRAP for strawberry leaf extracts.

3.1.3. Pharmacodynamic interactions

No data available.

3.1.4. Conclusions

The leaves from *Fragaria vesca* L., *Fragaria moschata* Weston, *Fragaria viridis* Weston, *Fragaria x ananassa* (Weston) Duchesne ex Rozier, are traditionally used for drinking as herbal tea in Europe for promoting diuresis and to treat mild diarrhoeas in children.

The scientific information available on the pharmacological activity of *Fragaria* leaves is limited. One study was performed with a dosage of 1 g/kg in rats after oral administration showed no significant influence in diuresis. Some reported pharmacological effects are partially consistent with the traditional use.

The astringent effect of strawberry is possibly due to the free or condensed tannoids content (at least 3% referred to dried drug), although no pharmacology studies proving the antidiarrheal activity have been published.

3.2. Overview of available pharmacokinetic data regarding the herbal substance(s), herbal preparation(s) and relevant constituents thereof

No data available.

3.3. Overview of available toxicological data regarding the herbal substance(s)/herbal preparation(s) and constituents thereof

3.3.1. Single dose toxicity

Herbal preparations

There are no data available on the acute toxicity of *Fragaria* leaves.

3.3.2. Repeated dose toxicity

Subacute, Chronic Toxicity

There are no data available.

3.3.3. Genotoxicity

Mutagenicity

There are no data available on the preparations covered by the monograph.

3.3.4. Carcinogenicity

No data available.

3.3.5. Reproductive and developmental toxicity

No data available.

3.3.6. Local tolerance

No data available.

3.3.7. Other special studies

Cytotoxic activity - *in vitro*

Liberal *et al* (2015) studied cytotoxic activity of an ellagitannin-enriched fraction (EEF) from hydroalcoholic extract *Fragaria vesca* leaves on the cultured human hepatic carcinoma cell line HepG2 (ATCC HB-8065). The hepatic cells viability after treatment with of both EEF and crude hydroalcoholic extract was determined and the IC₅₀ was evaluated. It was found, that different concentrations of EEF during 24 hours exposure induced: IC₅₀=113 µg/ml; IC₄₅=80 µg/ml; IC₄₀=56 µg/ml; IC₂₅=23 µg/ml; IC₁₅=9 µg/ml. Influence of the EEF on the distribution of G0/G1, S and G2/M phases cycle of HepG2 cells was also analysed via flow cytometry. The proliferation of the cells was dose-dependently decreased. Higher concentrations of the EEF induced an increase in cells in the G2/M phase whereas lower doses promoted a significant increase in cells in G1 phase when compared to control cells. In order to evaluate cell death and to discriminate between apoptosis and necrosis, cells were incubated with different concentrations of EEF for 24 h and then stained with annexin V-FITC/PI. The two higher concentrations of EEF promoted an increase in necrotic cells (annexin V-negative/PI-positive cells) and this increase was accompanied by a rise (statistically insignificant) of annexin V-positive/PI-positive cells that correspond to late apoptotic/necrotic cells. Thus, EEF induced features of necrosis and to some extent apoptosis in HepG2 cells. Cytotoxic activity of strawberry leaves extract was also detected on mouse L1210 leukaemia cells (910mg gave 60-79% inhibition) (Goun *et al.*, 2002). Skupień *et al.* (2006) observed strawberry leaf extract cytotoxic for HL60 cell line and its MDR sublines and Liberal *et al.* (2015) found strawberry leaf extract cytotoxic in a human hepatic carcinoma cell line (HepG2-ATCC HB-8065).

Assessor's comments:

The studies on cytotoxic activity of several herbal fractions were focused on possible antileukemic use, not on safety aspects of the preparations when they are used in patients. For this reason, the value of

the data for the assessment of herbal infusions which have been used traditionally by patients, is limited.

3.3.8. Conclusions

No toxicity studies are available for *Fragaria* leaves water extract and other extracts.

Tests on toxicity, genotoxicity and carcinogenicity have not been performed.

The US American Herbal Products Association considers strawberry leaf as safe (Class 1) and no clinically relevant interactions are expected (Class A) (Gardner and McGuffin 2013).

3.4. Overall conclusions on non-clinical data

The scientific information available on the pharmacological activity of *Fragaria* leaves is scarce.

Results from relevant non-clinical experimental studies on the influence on diuresis are scarce and non-conclusive.

The content of polyphenols such as elagitanins, agrimoniin, pedunculagin, gallic and elagic acids and procyanidins may partially explain the traditional use of the wild strawberry leaf teas, with mild astringent, anti-inflammatory and antimicrobial properties of the tannins in symptomatic treatment of mild diarrhoeas.

There is no non-clinical information on the safety of *Fragaria* leaves. As there is no information on reproductive and developmental toxicity, the use during pregnancy and lactation cannot be recommended.

Tests on genotoxicity and carcinogenicity have not been performed.

4. Clinical Data

4.1. Clinical pharmacology

4.1.1. Overview of pharmacodynamic data regarding the herbal substance(s)/preparation(s) including data on relevant constituents

No data available.

Clinical Studies

No data available.

4.2. Clinical Efficacy

4.2.1. Dose response studies

No data available.

4.2.2. Clinical studies (case studies and clinical trials)

Studies with potential relevance for WEU indication(s)

Not available.

Other studies

Pilot data are available from the abstract of the PhD thesis of Sneha (2019, University of Health Sciences in Bangalore). The author observed 60 patients with diagnosed minor aphthous ulcers, divided into 3 groups for 20 patients, administered strawberry leaf extract, raspberry leaf extract topically on mucosa or cellulose gel alone as control. The patients were advised to use the gel 3 times a day. Clinical evaluation contained pain assessment (on a base of VAS), ulcer size and questionnaire about acceptability, taste, texture and ease of use. The author observed significant reduction of pain on a day 4th ($p=0.001$) and on a day 7th ($p=0.020$). Strawberry leaf extract gel, in comparison to the control gel was declared to give significant pain reduction to day 2 ($p=0.001$ and day 4 ($P=0.002$). The taste, texture and tolerability were acceptable by majority of the patients.

4.3. Clinical studies in special populations (e.g. elderly and children)

No data available.

4.4. Overall conclusions on clinical pharmacology and efficacy

No data available.

5. Clinical Safety/Pharmacovigilance

5.1. Overview of toxicological/safety data from market overview

There are no data available with respect to adverse effects related to *Fragaria* leaves or corresponding preparations use (Blaschek *et al.* 2006); also AHPA Safety Handbook (Gardner and McGuffin 2013) indicated strawberry leaves can be safely consumed when used appropriately and there are no restrictions to use it as flavouring agent in herbal teas (Bundesanzeiger 1990, DeSmet *et al.* 1993; Grattan and Harman 1985; Rossoff *et al.* 2002; Van Wyk and Wink 2004).

No reports on adverse reactions for *Fragariae folium* or wild strawberry leaf were found in the pharmacovigilance databases in years 2018-2024.

This overview is not exhaustive. It is provided for information only and reflects the situation at the time when it was established.

5.2. Patient exposure

No data available.

5.3. Adverse events, serious adverse events and deaths

No data available.

5.4. Laboratory findings

No data available.

5.5. Safety in special populations and situations

5.5.1. Use in children and adolescents

For indication 1). The use in children has been reported in bibliography but without posology details in the age groups. Thus, it can be accepted only for adolescents, adults and elderly.

For indication 2). The use in children has been reported and thus, it can be accepted for children from 12 years of age and adolescents.

5.5.2. Contraindications

Hypersensitivity to the strawberry leaf has not been reported.

However, hypersensitivity to strawberry fruit is known but it is not a subject of the assessment. Strawberry leaf should not contain fruits. Some allergen genes were found in a wild strawberry fruit proteins (PR-10, nsLTP and profiling) what needed to be further studied (Hyun and Kim 2011).

In the bibliography is cited opinion on the Strawberry leaf risk from Commission E monograph: *Strawberry leaf may elicit allergic reactions in persons hypersensitive to strawberry fruit* (Wichtl 1994) although the source of the information is not available. Hypersensitivity to strawberry leaf can't be excluded.

5.5.3. Special Warnings and precautions for use

There are no adverse effects reported derived from the use of strawberry leaves.

The use in children under 12 years of age has not been established.

For Indication 1)

If complaints or symptoms such as fever, dysuria, spasms or blood in urine occur during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.

Because adequate fluid intake is required during treatment (see section 4.2. Method of administration), *Fragaria vesca* L.; *Fragaria moschata* West.; *Fragaria viridis* West.; *Fragaria x ananassa* (West.) Duchesne ex Rozier, folium (wild strawberry leaf) is not recommended for patients with conditions where reduced fluid intake was advised.

For Indication 2)

If diarrhoea recurs or bloody stools occur, a doctor or qualified health care practitioner should be consulted.

5.5.4. Drug interactions and other forms of interaction

No data available.

5.5.5. Fertility, pregnancy and lactation

No data available.

5.5.6. Overdose

No cases of overdose have been reported.

5.5.7. Effects on ability to drive or operate machinery or impairment of mental ability

No data available.

5.5.8. Safety in other special situations

Not applicable

5.6. Overall conclusions on clinical safety

Based on the information on traditional use, comminuted *Fragaria* leaves, are not considered harmful in the specified condition of use.

The traditional use for the relief of symptoms associated with minor urinary tract complaints and for the symptomatic treatment of mild diarrhoea (Indications 1 and 2) is documented for adults.

In mild diarrhoea (Indication 2) the use in children under 12 years of age has not been established.

The use is contraindicated for patients with hypersensitivity to the active substance.

For Indication 1)

If complaints or symptoms such as fever, dysuria, spasms or blood in urine occur during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.

Because adequate fluid intake is required during treatment (see section 4.2. Method of administration), *Fragaria vesca* L.; *Fragaria moschata* West.; *Fragaria viridis* West.; *Fragaria x ananassa* (West.) Duchesne ex Rozier, folium (wild strawberry leaf) is not recommended for patients with conditions where reduced fluid intake was advised.

For Indication 2)

If recurrent diarrhoea or bloody stools occur, a doctor or a qualified health care practitioner should be consulted.

Safety data in special populations and situations are not available.

Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy is not recommended

6. Overall conclusions

Well-established use cannot be accepted for *Fragaria vesca* L., *Fragaria moschata* Weston, *Fragaria viridis* Weston, *Fragaria x ananassa* (Weston) Duchesne ex Rozier, folium, due to the lack of data to recognise efficacy and the absence of medicinal products in the European Union.

The requirements for traditional medicinal use according to Article 16d (1), Article 16f and Article 16h of Directive 2001/83/EC are considered fulfilled. Traditional medicinal use of *Fragaria vesca* L., *Fragaria moschata* Weston, *Fragaria viridis* Weston, *Fragaria x ananassa* (Weston) Duchesne ex Rozier, folium, is documented in several handbooks throughout a period of at least 30 years. The comminuted herbal substance from *Fragaria* can be considered as safe when used in recommended dosages under the conditions specified in the monograph.

The comminuted herbal substance of *Fragaria vesca*, *F. moschata*, *F. viridis* and *Fragaria x ananassa* leaves for use in aqueous preparations (infusions and decoctions) is described in handbooks to increase the amount of urine in adults and to treat mild diarrhoea in children, but with no information regarding posology in paediatric age groups below 12 years.

Long-standing traditional medicinal use of the wild strawberry leaves within the European Union for at least 30 years according to Directive 2004/24/EC is considered fulfilled for the comminuted herbal substance and indications:

1. *Traditional herbal medicinal product used for the relief of symptoms associated with minor urinary tract complaints in addition to the general recommendation of a sufficient fluid intake to increase the amount of urine.*
2. *Traditional herbal medicinal product for the symptomatic treatment of mild diarrhoea.*

The use of wild strawberry leaves infusions and decoctions cannot be established for children below 12 years.

Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. No fertility data are available.

A European Union list entry is not supported due to lack of adequate data on genotoxicity.

Annex